{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T00:13:43Z","timestamp":1794701623649,"version":"4.9.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T00:00:00Z","timestamp":1647043200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T00:00:00Z","timestamp":1647043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background\/aims<\/jats:title>\n                    <jats:p>To evaluate 1-year success rates and safety profile of Preserflo\u2122 Microshunt in glaucoma patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Retrospective multicentre cohort study of 100 consecutive eyes (91 patients) from four tertiary-referral glaucoma centres. Four intraocular pressure (IOP) criteria were defined: A: IOP\u2009\u2264\u200921\u2009mmHg+IOP reduction \u226520% from baseline; B: IOP\u2009\u2264\u200918\u2009mmHg+IOP reduction \u226520%; C: IOP\u2009\u2264\u200915\u2009mmHg+IOP reduction \u226525%; D: IOP\u226412\u2009mmHg+IOP reduction \u226530%. Success was defined as qualified or complete based on whether reached with or without medication. Primary outcome was success according to the above criteria. Secondary outcomes included: IOP, best-corrected visual acuity (BCVA), medication use, complications, postoperative interventions, and failure-associated factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Qualified and complete success rates (95% CI) at 12 months were 74%(66\u201383%) and 58%(49\u201369%) for criterion A, 72%(63\u201382%) and 57%(48\u201368%) for B, 52%(43\u201363%) and 47%(38\u201358%) for C, 29%(21\u201340%) and 26%(19\u201336%) for D. Overall median (interquartile range (IQR)) preoperative IOP decreased from 21.5(19\u201328)\u2009mmHg to 13(11\u201316)\u2009mmHg at 12 months. BCVA was not significantly different up to 12 months (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.79). Preoperative median (IQR) number of medications decreased from 3 (2\u20133) to 0 (0\u20131) at 12 months. Twelve eyes underwent needling, five surgical revision and one device removal due to corneal oedema. There were no hypotony-related complications. Non-Caucasian ethnicity was the only risk factor consistently associated with increased failure.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Preserflo\u2122 Microshunt is a viable surgical option in glaucoma patients, with reasonable short-term success rates, decreased medications use, excellent safety profile, smooth postoperative care, and rapid learning curve. Success rates for the most stringent IOP cutoffs were modest, indicating that it may not be the optimal surgery when very low target IOP is required.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41433-022-01995-7","type":"journal-article","created":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T23:35:27Z","timestamp":1647041727000},"page":"644-649","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Short-term safety and efficacy of Preserflo\u2122 Microshunt in glaucoma patients: a multicentre retrospective cohort study"],"prefix":"10.1038","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2003-5895","authenticated-orcid":false,"given":"Raj","family":"Bhayani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Maria","family":"Mart\u00ednez de la Casa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Figus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karsten","family":"Klabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Rabiolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Mercieca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,12]]},"reference":[{"key":"1995_CR1","doi-asserted-by":"publisher","first-page":"3182935","DOI":"10.1155\/2017\/3182935","volume":"2017","author":"DZ Chen","year":"2017","unstructured":"Chen DZ, Sng CCA. Safety and efficacy of microinvasive glaucoma surgery. J Ophthalmol. 2017;2017:3182935.","journal-title":"J Ophthalmol"},{"key":"1995_CR2","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.jcjo.2016.07.013","volume":"52","author":"R Conlon","year":"2017","unstructured":"Conlon R, Saheb H. Ahmed, II. Glaucoma treatment trends: a review. Can J Ophthalmol. 2017;52:114\u201324.","journal-title":"Can J Ophthalmol"},{"key":"1995_CR3","doi-asserted-by":"crossref","unstructured":"Holland LJ, Mercieca KJ, Kirwan JF. Effect of COVID-19 pandemic on glaucoma surgical practices in the UK. Br J Ophthalmol. 2021.","DOI":"10.1136\/bjophthalmol-2021-319062"},{"key":"1995_CR4","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1001\/archopht.124.12.1742","volume":"124","author":"AC Acosta","year":"2006","unstructured":"Acosta AC, Espana EM, Yamamoto H, Davis S, Pinchuk L, Weber BA, et al. A newly designed glaucoma drainage implant made of poly(styrene-b-isobutylene-b-styrene): biocompatibility and function in normal rabbit eyes. Arch Ophthalmol. 2006;124:1742\u20139.","journal-title":"Arch Ophthalmol"},{"key":"1995_CR5","doi-asserted-by":"publisher","first-page":"e58","DOI":"10.1097\/IJG.0000000000000368","volume":"25","author":"JF Batlle","year":"2016","unstructured":"Batlle JF, Fantes F, Riss I, Pinchuk L, Alburquerque R, Kato YP, et al. Three-year follow-up of a novel aqueous humor MicroShunt. J Glaucoma. 2016;25:e58\u201365.","journal-title":"J Glaucoma"},{"key":"1995_CR6","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1093\/rb\/rbw005","volume":"3","author":"L Pinchuk","year":"2016","unstructured":"Pinchuk L, Riss I, Batlle JF, Kato YP, Martin JB, Arrieta E, et al. The use of poly(styrene-block-isobutylene-block-styrene) as a microshunt to treat glaucoma. Regen Biomater. 2016;3:137\u201342.","journal-title":"Regen Biomater"},{"key":"1995_CR7","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.ajo.2020.02.020","volume":"215","author":"MB Schlenker","year":"2020","unstructured":"Schlenker MB, Durr GM, Michaelov E, Ahmed IIK. Intermediate outcomes of a novel standalone ab externo SIBS microshunt with mitomycin C. Am J Ophthalmol. 2020;215:141\u201353.","journal-title":"Am J Ophthalmol"},{"key":"1995_CR8","doi-asserted-by":"crossref","unstructured":"Durr GM, Schlenker MB, Samet S, Ahmed IIK. One-year outcomes of stand-alone ab externo SIBS microshunt implantation in refractory glaucoma. Br J Ophthalmol. 2020;106:71\u20139.","DOI":"10.1136\/bjophthalmol-2020-317299"},{"key":"1995_CR9","doi-asserted-by":"crossref","unstructured":"Baker ND, Barnebey HS, Moster MR, Stiles MC, Vold SD, Khatana AK, et al. Ab-externo MicroShunt versus trabeculectomy in primary open-angle glaucoma: 1-year results from a 2-year randomized, multicenter study. Ophthalmology. 2021;128:1710\u201321.","DOI":"10.1016\/j.ophtha.2021.05.023"},{"key":"1995_CR10","doi-asserted-by":"crossref","unstructured":"Beckers HJM, Aptel F, Webers CAB, Bluwol E, Martinez-de-la-Casa JM, Garcia-Feijoo J, et al. Safety and effectiveness of the PRESERFLO(R) MicroShunt in primary open-angle glaucoma: results from a 2-year multicenter study. Ophthalmol Glaucoma. 2021;28;179\u20134.","DOI":"10.1016\/j.ogla.2021.07.008"},{"key":"1995_CR11","unstructured":"Shaarawy TM, Sherwood MB, Grehn F. Guidelines on design and reporting of glaucoma surgical trials. Kugler Publications; 2009."},{"key":"1995_CR12","doi-asserted-by":"crossref","unstructured":"Therneau TM, Grambsch PM. Modeling survival data: extending the Cox model. Springer-Verlag New York: New York; 2000.","DOI":"10.1007\/978-1-4757-3294-8"},{"key":"1995_CR13","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/(SICI)1097-0258(19970228)16:4<385::AID-SIM380>3.0.CO;2-3","volume":"16","author":"R Tibshirani","year":"1997","unstructured":"Tibshirani R. The Lasso method for variable selection in the Cox model. Stat Med. 1997;16:385\u201395.","journal-title":"Stat Med"},{"key":"1995_CR14","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.ophtha.2018.02.003","volume":"125","author":"SJ Gedde","year":"2018","unstructured":"Gedde SJ, Feuer WJ, Shi W, Lim KS, Barton K, Goyal S, et al. Treatment outcomes in the primary tube versus trabeculectomy study after 1 year of follow-up. Ophthalmology. 2018;125:650\u201363.","journal-title":"Ophthalmology"},{"key":"1995_CR15","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1007\/s00417-019-04251-z","volume":"257","author":"H Reitsamer","year":"2019","unstructured":"Reitsamer H, Sng C, Vera V, Lenzhofer M, Barton K, Stalmans I, et al. Two-year results of a multicenter study of the ab interno gelatin implant in medically uncontrolled primary open-angle glaucoma. Graefes Arch Clin Exp Ophthalmol. 2019;257:983\u201396.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1995_CR16","doi-asserted-by":"crossref","unstructured":"Scheres LMJ, Kujovic-Aleksov S, Ramdas WD, de Crom R, Roelofs LCG, Berendschot T, et al. XEN((R)) Gel Stent compared to PRESERFLO MicroShunt implantation for primary open-angle glaucoma: two-year results. Acta Ophthalmol. 2020;99:e433\u201340.","DOI":"10.1111\/aos.14602"},{"key":"1995_CR17","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1097\/IJG.0000000000001360","volume":"28","author":"S Olivari","year":"2019","unstructured":"Olivari S, Cutolo CA, Negri L, Cappelli F, Testa V, Iester M, et al. XEN implant fracture during needling procedure. J Glaucoma. 2019;28:1086\u20139.","journal-title":"J Glaucoma"},{"key":"1995_CR18","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.ogla.2020.08.013","volume":"4","author":"A Rabiolo","year":"2021","unstructured":"Rabiolo A, Leadbetter D, Alaghband P, Anand N. Primary deep sclerectomy in open-angle glaucoma: long-term outcomes and risk factors for failure. Ophthalmol Glaucoma. 2021;4:149\u201361.","journal-title":"Ophthalmol Glaucoma"},{"key":"1995_CR19","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.survophthal.2008.08.023","volume":"53","author":"E Mendrinos","year":"2008","unstructured":"Mendrinos E, Mermoud A, Shaarawy T. Nonpenetrating glaucoma surgery. Surv Ophthalmol. 2008;53:592\u2013630.","journal-title":"Surv Ophthalmol"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-022-01995-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-022-01995-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-022-01995-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T15:34:08Z","timestamp":1679844848000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-022-01995-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,12]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["1995"],"URL":"https:\/\/doi.org\/10.1038\/s41433-022-01995-7","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.741820823.793592126","asserted-by":"object"}]},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,12]]},"assertion":[{"value":"9 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Karl Mercieca has the following financial disclosures: Alcon: honorarium; Allergan\/Abbvie: consultancy, honorarium and research grants; Bausch & Lomb: honorarium; IOPtima: consultancy; Ivantis: research grants; Santen: consultancy and honorarium; Thea: honorarium; Topcon: honorarium. The other authors have no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}